Skip to main content

Table 3 Univariate analysis for overall survival and local control

From: Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up

Covariate categories N OS (%) p LC (%) p
3 years 5 years 3 years 5 years
Age, years
 > 70 24 25.0 ± 8.8 16.7 ± 7.6 0.57 64.2 ± 4.7 64.2 ± 5.9 0.71
 < 70 37 35.1 ± 7.8 18.9 ± 6.4 82.3 ± 4.4 82.3 ± 5.6
Gender
 Male 35 20.6 ± 6.9 11.8 ± 5.5 0.01 78.1 ± 4.3 78.1 ± 5.4 0.97
 Female 26 44.4 ± 9.6 25.9 ± 8.4 81.8 ± 4.1 81.8 ± 5.4
Cancer type
 Colorectal 29 41.1 ± 7.5 27.3 ± 8.1 < 0.001 75.3 ± 4.7 75.3 ± 5.7 0.47
 Breast cancer 11 33.0 ± 7.3 20.1 ± 6.9 86.8 ± 4.8 86.8 ± 5.7
 Gynecological cancer 7 56.8 ± 6.9 27.8 ± 7.3 86.1 ± 4.7 86.1 ± 5.6
 Other 14 10.2 ± 7.2 80.0 ± 4.4
Number of metastases
 1 48 42.8 ± 13.2 28.6 ± 12.1 0.22 82.0 ± 4.5 82.0 ± 5.4 0.28
 2–3 13 27.7 ± 6.5 14.9 ± 5.2 67.3 ± 4.7 67.3 ± 5.6
Size of metastases
 < 3 cm 32 28.1 ± 7.9 15.6 ± 6.4 0.46 77.2 ± 4.3 77.2 ± 5.5 0.60
 > 3 cm 29 34.4 ± 8.8 20.7 ± 7.5 81.9 ± 4.3 81.9 ± 5.9
Timing of metastasis
 Synchronous 24 29.3 ± 6.5 17.0 ± 5.5 0.93
 Metachronous 37 32.2 ± 8.1 19.3 ± 6.9
Time since diagnosis, mo
 ≤ 12 35 31.4 ± 7.8 17.1 ± 6.4 0.91
 > 12 26 30.8 ± 9.0 19.2 ± 7.7
Prior local therapy
 Yes 27 33.3 ± 9.1 11.1 ± 6.1 0.54 65.8 ± 4.6 66.7 ± 5.7 0.06
 No 34 29.4 ± 7.8 23.5 ± 7.3 87.1 ± 4.8 87.1 ± 5.8
Pre-SBRT chemotherapy
 0–1 schedule 23 43.5 ± 10.3 30.4 ± 9.6 0.10
 2–3-4 schedules 38 23.7 ± 6.9 10.5 ± 5.0
Extrahepatic disease
 Yes 21 33.3 ± 10.3 14.3 ± 7.6 0.88
 No 40 30.0 ± 7.2 20.0 ± 6.3